Evidence map›Paper›PMID 39734483›Full record

Trial reportWorld journal of stem cells2024

Preliminary evidence of renal function improvement in chronic progressive kidney disease using autologous CD34

Takayasu Ohtake, Tsutomu Sato, Toshitaka Tsukiyama, Suguru Muraoka, Ayaka Mitomo, Haruka Maruyama, Mizuki Yamano, Yasuhiro Mochida, Kunihiro Ishioka, Machiko Oka and 5 more

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in World journal of stem cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Takayasu OhtakeRegenerative Medicine, The Center for Cell Therapy & Regenerative Medicine, Shonan Kamakura General Hospital, Kamakura 247-8533, Kanagawa, Japan.
Tsutomu SatoClinical Laboratory, Shonan Kamakura General Hospital, Kamakura 247-8533, Kanagawa, Japan.
Toshitaka TsukiyamaDepartment of Radiology and Interventional Radiology, Shonan Kamakura General Hospital, Kamakura 247-8533, Japan.
Suguru MuraokaKidney Disease and Transplant Center, Shonan Kamakura General Hospital, Kamakura 247-8533, Kanagawa, Japan.
Ayaka MitomoKidney Disease and Transplant Center, Shonan Kamakura General Hospital, Kamakura 247-8533, Kanagawa, Japan.
Haruka MaruyamaKidney Disease and Transplant Center, Shonan Kamakura General Hospital, Kamakura 247-8533, Kanagawa, Japan.
Mizuki YamanoKidney Disease and Transplant Center, Shonan Kamakura General Hospital, Kamakura 247-8533, Kanagawa, Japan.
Yasuhiro MochidaKidney Disease and Transplant Center, Shonan Kamakura General Hospital, Kamakura 247-8533, Kanagawa, Japan.
Kunihiro IshiokaKidney Disease and Transplant Center, Shonan Kamakura General Hospital, Kamakura 247-8533, Kanagawa, Japan.
Machiko OkaKidney Disease and Transplant Center, Shonan Kamakura General Hospital, Kamakura 247-8533, Kanagawa, Japan.
Hidekazu MoriyaKidney Disease and Transplant Center, Shonan Kamakura General Hospital, Kamakura 247-8533, Kanagawa, Japan.
Sumi HidakaKidney Disease and Transplant Center, Shonan Kamakura General Hospital, Kamakura 247-8533, Kanagawa, Japan.
Haruchika MasudaRegenerative Medicine, Shonan Research Institute of Innovative Medicine, Kamakura 247-8533, Kanagawa, Japan.
Takayuki AsaharaRegenerative Medicine, Shonan Research Institute of Innovative Medicine, Kamakura 247-8533, Kanagawa, Japan.
Shuzo KobayashiKidney Disease and Transplant Center, Shonan Kamakura General Hospital, Kamakura 247-8533, Kanagawa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo date, no specific treatment has been established to reverse progressive chronic kidney disease (CKD).

aimTo evaluate the safety and efficacy of autologous CD34

methodsThe estimated glomerular filtration rate (eGFR) at the beginning of the study was 15.0-28.0 mL/minute/1.73 m

resultsFour patients were enrolled and completed the study. Three of four patients showed improvement in eGFR slope (eGFR slope > 0 mL/minute/1.73 m

conclusionIn conclusion, our findings suggest that repetitive peripheral blood-derived autologous CD34

Indexed as

CD34+ cellChronic kidney diseaseClinical trialGranulocyte colony-stimulating factorRegenerative therapy

Identifiers

PMID39734483
PMCPMC11669983

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.